|
Immunohistochemical biomarkers
|
PHA
|
EHE
|
MHP
|
IHE
|
|---|
|
Epithelial marker
|
|
CK
|
7 (64%)
|
8 (53%)
|
0
|
2 (15%)
|
|
Hepatocytes
|
6 (55%)
|
4 (27%)
|
0
|
0
|
|
CK8/18
|
6 (55%)
|
6 (40%)
|
0
|
0
|
|
Vascular endothelial marker
|
|
CD31
|
11 (100%)
|
15 (100%)
|
3 (100%)
|
13 (100%)
|
|
CD34
|
11 (100%)
|
15 (100%)
|
3 (100%)
|
13 (100%)
|
|
ERG
|
9 (82%)
|
13 (87%)
|
2 (67%)
|
13 (100%)
|
|
FaVIII
|
9 (82%)
|
9 (60%)
|
1 (33%)
|
7 (54%)
|
|
FLI-1
|
9 (82%)
|
9 (60%)
|
1 (33%)
|
7 (54%)
|
|
Mesenchymal marker
|
|
Vimentin
|
4 (36%)
|
2 (13%)
|
0
|
0
|
|
EMA
|
3 (27%)
|
0
|
0
|
0
|
|
CD117
|
2 (18%)
|
0
|
0
|
0
|
|
Dog-1
|
0
|
0
|
0
|
0
|
|
Perivascular epithelioid cell marker
|
|
HMB45
|
0
|
0
|
2 (67%)
|
0
|
|
Melan-A
|
0
|
0
|
2 (67%)
|
0
|
|
Cell proliferation marker
|
|
Ki-67, median, % (range)
|
30 (1–60)
|
5 (2–20)
|
30 (10–30)
|
10 (1–20)
|
- Note: PHA Primary hepatic angiosarcoma; EHE Epithelioid hemangioendothelioma; MHP Malignant hemangiopericytoma; IHE Infantile hemangioendothelioma; CK Cytokeratin; EMA Epithelial membrane antigen; CD Cluster of differentiation; HMB45 Human melanoma black monoclonal antibody
